Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
12,064 Hematology
clinical trials

Hematology, Oncology Clinical Trial
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
Status: Enrolling, Phase II
Updated: 12/31/1969
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Gastroenterology, Hematology, Immunology / Infectious Diseases Clinical Trial
Harvoni Treatment Porphyria Cutanea Tarda
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Texas Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
Hematology Clinical Trial
Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma
Status: Enrolling, Phase I
Updated: 12/31/1969
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)
Status: Enrolling, Phase I, II
Updated: 12/31/1969
Virginia Cancer Specialists, PC
mi
from
Fairfax, VA
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies
Status: Enrolling, Phase I
Updated: 12/31/1969
Wexner Medical Center at the Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies
Status: Enrolling, Phase I
Updated: 12/31/1969
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies
Status: Enrolling, Phase I
Updated: 12/31/1969
University of Utah, Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
High-Intensity Parent Intervention Program in Improving Learning and School Functioning in Latino Children With Acute Leukemia or Lymphoblastic Lymphoma
Status: Enrolling
Updated: 12/31/1969
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Longterm Follow-up of Subjects Treated With bb2121
Status: Enrolling, Phase
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Longterm Follow-up of Subjects Treated With bb2121
Status: Enrolling, Phase
Updated: 12/31/1969
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Sinai Hospital of Baltimore
mi
from
Baltimore, MD
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Valley Children's Hospital
mi
from
Madera, CA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Randall Children's Hospital at Legacy Emanuel
mi
from
Portland, OR
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Hospital of San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Multiple Myeloma Clinical Trial
Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
Status: Enrolling, Phase II
Updated: 2/19/2018
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Dell Children's Medical Center of Central Texas
mi
from
Austin, TX
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Hospital of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Blank Children's Hospital
mi
from
Des Moines, IA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Hospital Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Saint Luke's Mountain States Tumor Institute
mi
from
Boise, ID
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
BI-LO Charities Children's Cancer Center
mi
from
Greenville, SC
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Mercy Hospitals and Clinics
mi
from
Kansas City, MO
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Arkansas Children's Hospital
mi
from
Little Rock, AR
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
West Virginia University Healthcare
mi
from
Morgantown, WV
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Cook Children's Medical Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Nicklaus Children's Hospital
mi
from
Miami, FL
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Ochsner Medical Center Jefferson
mi
from
New Orleans, LA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Kaiser Permanente-Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Hospital and Medical Center of Omaha
mi
from
Omaha, NE
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Arnold Palmer Hospital for Children
mi
from
Orlando, FL
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Nemours Children's Hospital
mi
from
Orlando, FL
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Mercy Hospital Saint Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Hematology, Oncology, Orthopedics / Podiatry Clinical Trial
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Status: Enrolling, Phase IV
Updated: 12/31/1969
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Hematology, Oncology, Orthopedics / Podiatry Clinical Trial
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Status: Enrolling, Phase IV
Updated: 12/31/1969
University of Vermont Medical Center
mi
from
Burlington, VT
Click here to add this to my saved trials
Hematology, Oncology, Orthopedics / Podiatry Clinical Trial
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Status: Enrolling, Phase IV
Updated: 12/31/1969
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Hematology, Oncology, Orthopedics / Podiatry Clinical Trial
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Status: Enrolling, Phase IV
Updated: 12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Hematology, Oncology, Orthopedics / Podiatry Clinical Trial
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Status: Enrolling, Phase IV
Updated: 12/31/1969
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Hematology, Oncology, Orthopedics / Podiatry Clinical Trial
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Status: Enrolling, Phase IV
Updated: 12/31/1969
Yakima Valley Memorial Hospital
mi
from
Yakima, WA
Click here to add this to my saved trials
Myelofibrosis Clinical Trial
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
Status: Enrolling
Updated: 7/27/2017
Center for International Blood and Marrow Transplant Research
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University Medical Center of Southern Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Mission Hospital-Memorial Campus
mi
from
Asheville, NC
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Saint Luke's Mountain States Tumor Institute
mi
from
Boise, ID
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Dayton Children's Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
BI-LO Charities Children's Cancer Center
mi
from
Greenville, SC
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
East Tennessee Children's Hospital
mi
from
Knoxville, TN
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Arkansas Children's Hospital
mi
from
Little Rock, AR
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Miami Miller School of Medicine-Sylvester Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
West Virginia University Healthcare
mi
from
Morgantown, WV
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Arnold Palmer Hospital for Children
mi
from
Orlando, FL
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Hemophilia A With Inhibitors Clinical Trial
A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)
Status: Enrolling, Phase IV
Updated: 12/31/1969
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Hemophilia A With Inhibitors Clinical Trial
A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)
Status: Enrolling, Phase IV
Updated: 12/31/1969
Children's Hospital of Michigan
mi
from
Detroit, MI
Click here to add this to my saved trials
Hemophilia A With Inhibitors Clinical Trial
A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)
Status: Enrolling, Phase IV
Updated: 12/31/1969
El Paso Children's Hospital
mi
from
El Paso, TX
Click here to add this to my saved trials
Hemophilia A With Inhibitors Clinical Trial
A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)
Status: Enrolling, Phase IV
Updated: 12/31/1969
Cook Children's Medical Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Hemophilia A With Inhibitors Clinical Trial
A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)
Status: Enrolling, Phase IV
Updated: 12/31/1969
Indiana Hemophilia and Thrombosis Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
Status: Enrolling, Phase II
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Bacteremia Clinical Trial
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics
Status: Enrolling, Phase I
Updated: 12/31/1969
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Acute Myeloid Leukemia Clinical Trial
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
Status: Enrolling, Phase III
Updated: 12/31/1969
The University of Arizona Cancer Center - North Campus
mi
from
Tucson, AZ
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Hospital of The King's Daughters
mi
from
Norfolk, VA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Nemours Children's Clinic - Pensacola
mi
from
Pensacola, FL
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Methodist Children's Hospital of South Texas
mi
from
San Antonio, TX
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Alfred I. duPont Hospital for Children
mi
from
Wilmington, DE
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Eastern Maine Medical Center
mi
from
Bangor, ME
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Miller Children's and Women's Hospital Long Beach
mi
from
Long Beach, CA
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University Medical Center
mi
from
Lubbock, TX
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Hematology, Immunology / Infectious Diseases, Oncology Clinical Trial
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
Status: Enrolling, Phase II
Updated: 12/31/1969
Children's Hospitals and Clinics of Minnesota - Minneapolis
mi
from
Minneapolis, MN
Click here to add this to my saved trials
1 … 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 … 121